Products Erenumab was approved in many countries, in the EU, and in the United States in 2018 as a solution for injection in a prefilled pen and a prefilled syringe (Aimovig, Novartis / Amgen). Structure and properties Erenumab is a human IgG2 monoclonal antibody directed against the CGRP receptor. It has a molecular weight of … Erenumab
Products Eptinezumab is in the development phase and is not yet commercially available. Structure and properties Eptinezumab is an IgG1 monoclonal antibody directed against CGRP. Effects Eptinezumab reduces the number of migraine attacks. The effects are due to binding of the antibody to CGRP, the calcitonin gene-related peptide. CGRP is a neuropeptide that plays an … Eptinezumab
Products Galcanezumab was approved in the United States and EU in 2018 and in many countries in 2019 as a solution for injection in a prefilled pen and a prefilled syringe (Emgality, Eli Lilly). Structure and properties Galcanezumab is a humanized IgG4 monoclonal antibody with a molecular mass of 147 kDa against CGRP. It is … Galcanezumab
Products Fremanezumab was approved in the United States in 2018 and in the EU and Switzerland in 2019 as a solution for injection for subcutaneous use (Ajovy). Structure and properties Fremanezumab is a humanized IgG2Δa/kappa monoclonal antibody directed against CGRP (calcitonin gene-related peptide). The antibody is produced by biotechnological methods, consists of 1324 amino acids, … Fremanezumab
